Table 2.

Classifications according to CTCAE vers. 5.0 for leukocytes, haemoglobin, platelets, and creatinine for patients treated with [¹⁷⁷Lu]Lu-PSMA I&T and [¹⁷⁷Lu]Lu-PSMA-617 at baseline and after the last available cycle. *For [¹⁷⁷Lu]Lu-PSMA-617, blood values were collected, with only platelets missing in 2 subjects. ^#For [¹⁷⁷Lu]Lu-PSMA-617, there were five grade III toxicities for haemoglobin and one grade III toxicity for platelets after the last cycle. At baseline, however, one event for each blood value was already recorded, and thus, the total number of toxicities in this cohort only increased by four after the last cycle for haemoglobin and remained stable for platelets. No other grade III/IV toxicities occurred for both compounds

		[177Lu]Lu-PSMA I&T					[177Lu]Lu-PSMA-617
		Grade 0	Grade I	Grade II	Grade III	Grade IV	Grade 0	Grade I	Grade II	Grade III	Grade IV
Leukocytes	Baseline	42/55 (76.4%)	12/55 (21.8%)	1/55 (1.8%)	0.0	0.0	42/55 (76.4%)	12/55 (21.8%)	0.0	1/55 (1.8%)	0.0
	Last cycle	30/55 (54.5%)	21/55 (38.2%)	4/55 (7.3%)	0.0	0.0	29/55 (52.7%)	23/55 (41.8%)	3/55 (5.5%)	0.0	0.0
Haemoglobin	Baseline	5/55 (9.1%)	39/55 (70.9%)	11/55 (20.0%)	0.0	0.0	0.0	41/55 (74.5%)	13/55 (23.6%)	1/55 (1.8%)	0.0
	Last cycle	4/55 (7.3%)	31/55 (56.4%)	19/55 (34.5%)	1/55 (1.8%)	0.0	1/55 (1.8%)	26/55 (47.3%)	23/55 (41.8%)	5/55 (9.1%)#	0.0
Platelets	Baseline	53/55 (96.4%)	2/55 (3.6%)	0.0	0.0	0.0	49/55 (89.1%)	5/55 (9.1%)	0.0	1/55 (1.8%)	0.0
	Last cycle*	44/55 (80.0%)	7/55 (12.7%)	4/55 (7.3%)	0.0	0.0	40/53 (75.5%)	12/53 (22.6%)	0.0	1/53 (1.9%)#	0.0
Creatinine	Baseline	44/55 (80.0%)	9/55 (16.4%)	2/55 (3.6%)	0.0	0.0	48/55 (87.3%)	5/55 (9.1%)	2/55 (3.6%)	0.0	0.0
	Last cycle	42/55 (76.4%)	11/55 (20.0%)	2/55 (3.6%)	0.0	0.0	46/55 (83.6%)	4/55 (7.3%)	5/55 (9.1%)	0.0	0.0